Dunad Therapeutics has struck a new multi-million dollar deal with Novartis



Biopharmaceutical company Dunad Therapeutics (Dunad) has annouced that it has entered into a strategic collaboration with Novartis, to develop orally bioavailable covalent and protein degrading small molecule drugs. Professor Patrick Gunning is the Co-founder, acting CEO and Chief Scientific Officer of Dunad Therapeutics and is thrilled to have entered this collaboration with Novartis. Here are a few stories in all major biotech news outlets following the big announcement on November 2, 2021:


Featured Posts
Recent Posts
Archive
Search By Tags
No tags yet.
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square